[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmPpz213sX690b7icpHbOjvK6sKcJFvOeSUA5sdjPg4c":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":84,"rows":91},"University of Sydney",[4],93,false,30,18,76220,27,61,[14,17,19,22,24,26,29,32],{"name":15,"count":16},"Lung Cancer",5,{"name":18,"count":16},"Diabetic Macular Oedema",{"name":20,"count":21},"Diabetic Retinopathy",4,{"name":23,"count":21},"Obesity",{"name":25,"count":21},"Cancer",{"name":27,"count":28},"Stroke",3,{"name":30,"count":31},"Breast Cancer",2,{"name":33,"count":31},"Prostate Cancer",[35,40,45,50,55,60,65,69,74,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04195139","Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM","2024-06-28","Nivolumab",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03998319","A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.","2024-12-31","Tenecteplase",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06444243","Psilocybin-assisted Therapy for Alcohol Use Disorder","2025-07","Psilocybin",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05408247","A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder","2025-11","N-acetyl cysteine",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT02446444","Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer","2026-06","Enzalutamide",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT01320345","The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.","2026-08-28","Fenofibrate",{"nctId":66,"briefTitle":67,"date":68,"intervention":59},"NCT02446405","Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer","2026-12-31",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT05709028","Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections","2027-08","Fosfomycin",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04136353","Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate","2028-01-31","Darolutamide",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT05018221","Better Evidence and Translation for Calciphylaxis","2029-12","Vitamin K1",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,117,149,171,189,207,225,254,272,290,308,326,353,371,395,413,436,454,472,494,512,530,548,570,611,634,652,670,695,721,739,780,805,831,849,876,894,922,940,965,983,1014,1032,1050,1068,1095,1113,1137,1155,1180,1205,1230,1254,1281,1310,1328,1346],{"intervention":54,"totalTrials":93,"cells":94},1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":115},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":93,"soonestReadout":53},[106],{"nctId":51,"briefTitle":52,"status":107,"phases":108,"primaryCompletion":53,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"RECRUITING",[89],"2026-11","2023-02-16",280,[113],"Alcohol Use Disorder (AUD)",[54],{"trials":116,"activeCount":97},[],{"intervention":59,"totalTrials":31,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":145,"NA":147},{"trials":120,"activeCount":97},[],{"trials":122,"activeCount":97},[],{"trials":124,"activeCount":97},[],{"trials":126,"activeCount":31,"soonestReadout":58},[127,138],{"nctId":66,"briefTitle":67,"status":128,"phases":129,"primaryCompletion":68,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":135},"ACTIVE_NOT_RECRUITING",[88],"2027-06-30","2014-03",1125,[134],"Prostatic Neoplasms",[59,136,137],"NSAA","LHRHA or Surgical Castration",{"nctId":56,"briefTitle":57,"status":128,"phases":139,"primaryCompletion":58,"completion":58,"start":131,"enrollment":140,"conditions":141,"interventions":142},[88],802,[134],[59,143,144],"Conventional NSAA","LHRHA",{"trials":146,"activeCount":97},[],{"trials":148,"activeCount":97},[],{"intervention":78,"totalTrials":93,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":167,"NA":169},{"trials":152,"activeCount":97},[],{"trials":154,"activeCount":97},[],{"trials":156,"activeCount":97},[],{"trials":158,"activeCount":93,"soonestReadout":77},[159],{"nctId":75,"briefTitle":76,"status":128,"phases":160,"primaryCompletion":77,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},[88],"2028-07-31","2020-03-31",1100,[33],[78,166],"Luteinizing Hormone-Releasing Hormone Analog",{"trials":168,"activeCount":97},[],{"trials":170,"activeCount":97},[],{"intervention":166,"totalTrials":93,"cells":172},{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":179,"PHASE4":185,"NA":187},{"trials":174,"activeCount":97},[],{"trials":176,"activeCount":97},[],{"trials":178,"activeCount":97},[],{"trials":180,"activeCount":93,"soonestReadout":77},[181],{"nctId":75,"briefTitle":76,"status":128,"phases":182,"primaryCompletion":77,"completion":161,"start":162,"enrollment":163,"conditions":183,"interventions":184},[88],[33],[78,166],{"trials":186,"activeCount":97},[],{"trials":188,"activeCount":97},[],{"intervention":136,"totalTrials":93,"cells":190},{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":203,"NA":205},{"trials":192,"activeCount":97},[],{"trials":194,"activeCount":97},[],{"trials":196,"activeCount":97},[],{"trials":198,"activeCount":93,"soonestReadout":68},[199],{"nctId":66,"briefTitle":67,"status":128,"phases":200,"primaryCompletion":68,"completion":130,"start":131,"enrollment":132,"conditions":201,"interventions":202},[88],[134],[59,136,137],{"trials":204,"activeCount":97},[],{"trials":206,"activeCount":97},[],{"intervention":137,"totalTrials":93,"cells":208},{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":215,"PHASE4":221,"NA":223},{"trials":210,"activeCount":97},[],{"trials":212,"activeCount":97},[],{"trials":214,"activeCount":97},[],{"trials":216,"activeCount":93,"soonestReadout":68},[217],{"nctId":66,"briefTitle":67,"status":128,"phases":218,"primaryCompletion":68,"completion":130,"start":131,"enrollment":132,"conditions":219,"interventions":220},[88],[134],[59,136,137],{"trials":222,"activeCount":97},[],{"trials":224,"activeCount":97},[],{"intervention":226,"totalTrials":93,"cells":227},"Bleomycin",{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":250,"NA":252},{"trials":229,"activeCount":97},[],{"trials":231,"activeCount":97},[],{"trials":233,"activeCount":97},[],{"trials":235,"activeCount":93,"soonestReadout":240},[236],{"nctId":237,"briefTitle":238,"status":107,"phases":239,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":245},"NCT02582697","Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours",[88],"2029-12-31","2014-02",500,[244],"Germ Cell Tumor",[226,246,247,248,249],"Etoposide","Cisplatin","Pegylated G-CSF","Filgrastim",{"trials":251,"activeCount":97},[],{"trials":253,"activeCount":97},[],{"intervention":246,"totalTrials":93,"cells":255},{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":268,"NA":270},{"trials":257,"activeCount":97},[],{"trials":259,"activeCount":97},[],{"trials":261,"activeCount":97},[],{"trials":263,"activeCount":93,"soonestReadout":240},[264],{"nctId":237,"briefTitle":238,"status":107,"phases":265,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":266,"interventions":267},[88],[244],[226,246,247,248,249],{"trials":269,"activeCount":97},[],{"trials":271,"activeCount":97},[],{"intervention":247,"totalTrials":93,"cells":273},{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":280,"PHASE4":286,"NA":288},{"trials":275,"activeCount":97},[],{"trials":277,"activeCount":97},[],{"trials":279,"activeCount":97},[],{"trials":281,"activeCount":93,"soonestReadout":240},[282],{"nctId":237,"briefTitle":238,"status":107,"phases":283,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":284,"interventions":285},[88],[244],[226,246,247,248,249],{"trials":287,"activeCount":97},[],{"trials":289,"activeCount":97},[],{"intervention":248,"totalTrials":93,"cells":291},{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":304,"NA":306},{"trials":293,"activeCount":97},[],{"trials":295,"activeCount":97},[],{"trials":297,"activeCount":97},[],{"trials":299,"activeCount":93,"soonestReadout":240},[300],{"nctId":237,"briefTitle":238,"status":107,"phases":301,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":302,"interventions":303},[88],[244],[226,246,247,248,249],{"trials":305,"activeCount":97},[],{"trials":307,"activeCount":97},[],{"intervention":249,"totalTrials":93,"cells":309},{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":322,"NA":324},{"trials":311,"activeCount":97},[],{"trials":313,"activeCount":97},[],{"trials":315,"activeCount":97},[],{"trials":317,"activeCount":93,"soonestReadout":240},[318],{"nctId":237,"briefTitle":238,"status":107,"phases":319,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":320,"interventions":321},[88],[244],[226,246,247,248,249],{"trials":323,"activeCount":97},[],{"trials":325,"activeCount":97},[],{"intervention":327,"totalTrials":93,"cells":328},"Methylprednisolone",{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":335,"PHASE4":349,"NA":351},{"trials":330,"activeCount":97},[],{"trials":332,"activeCount":97},[],{"trials":334,"activeCount":97},[],{"trials":336,"activeCount":93,"soonestReadout":341},[337],{"nctId":338,"briefTitle":339,"status":107,"phases":340,"primaryCompletion":341,"completion":341,"start":342,"enrollment":343,"conditions":344,"interventions":347},"NCT06474273","TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients",[88],"2030-06","2026-03-13",540,[345,346],"Rejection; Transplant, Kidney","Rejection; Transplant, Pancreas",[327,348],"Prednisone",{"trials":350,"activeCount":97},[],{"trials":352,"activeCount":97},[],{"intervention":348,"totalTrials":93,"cells":354},{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":361,"PHASE4":367,"NA":369},{"trials":356,"activeCount":97},[],{"trials":358,"activeCount":97},[],{"trials":360,"activeCount":97},[],{"trials":362,"activeCount":93,"soonestReadout":341},[363],{"nctId":338,"briefTitle":339,"status":107,"phases":364,"primaryCompletion":341,"completion":341,"start":342,"enrollment":343,"conditions":365,"interventions":366},[88],[345,346],[327,348],{"trials":368,"activeCount":97},[],{"trials":370,"activeCount":97},[],{"intervention":64,"totalTrials":93,"cells":372},{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":391,"NA":393},{"trials":374,"activeCount":97},[],{"trials":376,"activeCount":97},[],{"trials":378,"activeCount":97},[],{"trials":380,"activeCount":93,"soonestReadout":63},[381],{"nctId":61,"briefTitle":62,"status":128,"phases":382,"primaryCompletion":63,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":389},[88],"2026-12","2016-11-03",412,[387,20,388],"Type 1 Diabetes Mellitus","Diabetic Nephropathies",[64,390],"Inert lactose placebo",{"trials":392,"activeCount":97},[],{"trials":394,"activeCount":97},[],{"intervention":390,"totalTrials":93,"cells":396},{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":409,"NA":411},{"trials":398,"activeCount":97},[],{"trials":400,"activeCount":97},[],{"trials":402,"activeCount":97},[],{"trials":404,"activeCount":93,"soonestReadout":63},[405],{"nctId":61,"briefTitle":62,"status":128,"phases":406,"primaryCompletion":63,"completion":383,"start":384,"enrollment":385,"conditions":407,"interventions":408},[88],[387,20,388],[64,390],{"trials":410,"activeCount":97},[],{"trials":412,"activeCount":97},[],{"intervention":83,"totalTrials":93,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":432,"NA":434},{"trials":416,"activeCount":97},[],{"trials":418,"activeCount":97},[],{"trials":420,"activeCount":97},[],{"trials":422,"activeCount":93,"soonestReadout":82},[423],{"nctId":80,"briefTitle":81,"status":107,"phases":424,"primaryCompletion":82,"completion":82,"start":425,"enrollment":426,"conditions":427,"interventions":429},[88],"2021-08-26",350,[428],"Calciphylaxis",[83,430,431],"Magnesium citrate","Sodium Thiosulfate",{"trials":433,"activeCount":97},[],{"trials":435,"activeCount":97},[],{"intervention":430,"totalTrials":93,"cells":437},{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":450,"NA":452},{"trials":439,"activeCount":97},[],{"trials":441,"activeCount":97},[],{"trials":443,"activeCount":97},[],{"trials":445,"activeCount":93,"soonestReadout":82},[446],{"nctId":80,"briefTitle":81,"status":107,"phases":447,"primaryCompletion":82,"completion":82,"start":425,"enrollment":426,"conditions":448,"interventions":449},[88],[428],[83,430,431],{"trials":451,"activeCount":97},[],{"trials":453,"activeCount":97},[],{"intervention":431,"totalTrials":93,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":468,"NA":470},{"trials":457,"activeCount":97},[],{"trials":459,"activeCount":97},[],{"trials":461,"activeCount":97},[],{"trials":463,"activeCount":93,"soonestReadout":82},[464],{"nctId":80,"briefTitle":81,"status":107,"phases":465,"primaryCompletion":82,"completion":82,"start":425,"enrollment":426,"conditions":466,"interventions":467},[88],[428],[83,430,431],{"trials":469,"activeCount":97},[],{"trials":471,"activeCount":97},[],{"intervention":73,"totalTrials":93,"cells":473},{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":490,"NA":492},{"trials":475,"activeCount":97},[],{"trials":477,"activeCount":97},[],{"trials":479,"activeCount":97},[],{"trials":481,"activeCount":93,"soonestReadout":72},[482],{"nctId":70,"briefTitle":71,"status":107,"phases":483,"primaryCompletion":72,"completion":72,"start":484,"enrollment":485,"conditions":486,"interventions":488},[88],"2023-08-02",300,[487],"Urinary Tract Infections",[73,489],"Standard of care antibiotics",{"trials":491,"activeCount":97},[],{"trials":493,"activeCount":97},[],{"intervention":489,"totalTrials":93,"cells":495},{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":508,"NA":510},{"trials":497,"activeCount":97},[],{"trials":499,"activeCount":97},[],{"trials":501,"activeCount":97},[],{"trials":503,"activeCount":93,"soonestReadout":72},[504],{"nctId":70,"briefTitle":71,"status":107,"phases":505,"primaryCompletion":72,"completion":72,"start":484,"enrollment":485,"conditions":506,"interventions":507},[88],[487],[73,489],{"trials":509,"activeCount":97},[],{"trials":511,"activeCount":97},[],{"intervention":143,"totalTrials":93,"cells":513},{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":520,"PHASE4":526,"NA":528},{"trials":515,"activeCount":97},[],{"trials":517,"activeCount":97},[],{"trials":519,"activeCount":97},[],{"trials":521,"activeCount":93,"soonestReadout":58},[522],{"nctId":56,"briefTitle":57,"status":128,"phases":523,"primaryCompletion":58,"completion":58,"start":131,"enrollment":140,"conditions":524,"interventions":525},[88],[134],[59,143,144],{"trials":527,"activeCount":97},[],{"trials":529,"activeCount":97},[],{"intervention":144,"totalTrials":93,"cells":531},{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":536,"PHASE3":538,"PHASE4":544,"NA":546},{"trials":533,"activeCount":97},[],{"trials":535,"activeCount":97},[],{"trials":537,"activeCount":97},[],{"trials":539,"activeCount":93,"soonestReadout":58},[540],{"nctId":56,"briefTitle":57,"status":128,"phases":541,"primaryCompletion":58,"completion":58,"start":131,"enrollment":140,"conditions":542,"interventions":543},[88],[134],[59,143,144],{"trials":545,"activeCount":97},[],{"trials":547,"activeCount":97},[],{"intervention":44,"totalTrials":93,"cells":549},{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":566,"NA":568},{"trials":551,"activeCount":97},[],{"trials":553,"activeCount":97},[],{"trials":555,"activeCount":97},[],{"trials":557,"activeCount":93,"soonestReadout":43},[558],{"nctId":41,"briefTitle":42,"status":107,"phases":559,"primaryCompletion":43,"completion":68,"start":560,"enrollment":561,"conditions":562,"interventions":565},[88],"2021-10-14",445,[563,564],"STEMI","Elevated IMR (>32)",[44],{"trials":567,"activeCount":97},[],{"trials":569,"activeCount":97},[],{"intervention":571,"totalTrials":31,"cells":572},"Niacin",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":605,"PHASE4":607,"NA":609},{"trials":574,"activeCount":97},[],{"trials":576,"activeCount":97},[],{"trials":578,"activeCount":93,"soonestReadout":48},[579,591],{"nctId":46,"briefTitle":47,"status":580,"phases":581,"primaryCompletion":48,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":590},"NOT_YET_RECRUITING",[87],"2025-12","2024-09",90,[586,587,588,589],"Alcohol Use Disorder","Alcohol Dependence","Depression","Anxiety",[49,571],{"nctId":592,"briefTitle":593,"status":594,"phases":595,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":599,"interventions":603},"NCT05709353","MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder","UNKNOWN",[87],"2026-05","2023-09-19",120,[600,586,587,601,602],"PTSD","Post-traumatic Stress Disorder","Comorbidities and Coexisting Conditions",[604,571],"MDMA",{"trials":606,"activeCount":97},[],{"trials":608,"activeCount":97},[],{"trials":610,"activeCount":97},[],{"intervention":39,"totalTrials":93,"cells":612},{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":628,"PHASE4":630,"NA":632},{"trials":614,"activeCount":97},[],{"trials":616,"activeCount":97},[],{"trials":618,"activeCount":93,"soonestReadout":38},[619],{"nctId":36,"briefTitle":37,"status":128,"phases":620,"primaryCompletion":38,"completion":621,"start":622,"enrollment":623,"conditions":624,"interventions":626},[87],"2025-12-31","2018-02-22",103,[625],"Glioblastoma Multiforme",[39,627],"Temozolomide",{"trials":629,"activeCount":97},[],{"trials":631,"activeCount":97},[],{"trials":633,"activeCount":97},[],{"intervention":627,"totalTrials":93,"cells":635},{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":646,"PHASE4":648,"NA":650},{"trials":637,"activeCount":97},[],{"trials":639,"activeCount":97},[],{"trials":641,"activeCount":93,"soonestReadout":38},[642],{"nctId":36,"briefTitle":37,"status":128,"phases":643,"primaryCompletion":38,"completion":621,"start":622,"enrollment":623,"conditions":644,"interventions":645},[87],[625],[39,627],{"trials":647,"activeCount":97},[],{"trials":649,"activeCount":97},[],{"trials":651,"activeCount":97},[],{"intervention":49,"totalTrials":93,"cells":653},{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":664,"PHASE4":666,"NA":668},{"trials":655,"activeCount":97},[],{"trials":657,"activeCount":97},[],{"trials":659,"activeCount":93,"soonestReadout":48},[660],{"nctId":46,"briefTitle":47,"status":580,"phases":661,"primaryCompletion":48,"completion":582,"start":583,"enrollment":584,"conditions":662,"interventions":663},[87],[586,587,588,589],[49,571],{"trials":665,"activeCount":97},[],{"trials":667,"activeCount":97},[],{"trials":669,"activeCount":97},[],{"intervention":671,"totalTrials":93,"cells":672},"Aflibercept",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":679,"PHASE4":681,"NA":693},{"trials":674,"activeCount":97},[],{"trials":676,"activeCount":97},[],{"trials":678,"activeCount":97},[],{"trials":680,"activeCount":97},[],{"trials":682,"activeCount":97},[683],{"nctId":684,"briefTitle":685,"status":686,"phases":687,"primaryCompletion":688,"completion":688,"start":689,"enrollment":690,"conditions":691,"interventions":692},"NCT02432547","Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)","COMPLETED",[89],"2022-05-24","2017-06-15",48,[20],[671],{"trials":694,"activeCount":97},[],{"intervention":696,"totalTrials":93,"cells":697},"Naltrexone",{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":719},{"trials":699,"activeCount":97},[],{"trials":701,"activeCount":97},[],{"trials":703,"activeCount":97},[],{"trials":705,"activeCount":97},[],{"trials":707,"activeCount":97},[708],{"nctId":709,"briefTitle":710,"status":594,"phases":711,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT00120601","Trial for the Treatment of Alcohol Dependence",[89],"2005-06","2003-03",200,[716],"Alcoholism",[696,718],"Acamprosate",{"trials":720,"activeCount":97},[],{"intervention":718,"totalTrials":93,"cells":722},{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":729,"PHASE4":731,"NA":737},{"trials":724,"activeCount":97},[],{"trials":726,"activeCount":97},[],{"trials":728,"activeCount":97},[],{"trials":730,"activeCount":97},[],{"trials":732,"activeCount":97},[733],{"nctId":709,"briefTitle":710,"status":594,"phases":734,"completion":712,"start":713,"enrollment":714,"conditions":735,"interventions":736},[89],[716],[696,718],{"trials":738,"activeCount":97},[],{"intervention":740,"totalTrials":28,"cells":741},"Triamcinolone acetate",{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":746,"PHASE3":748,"PHASE4":776,"NA":778},{"trials":743,"activeCount":97},[],{"trials":745,"activeCount":97},[],{"trials":747,"activeCount":97},[],{"trials":749,"activeCount":97},[750,759,768],{"nctId":751,"briefTitle":752,"status":686,"phases":753,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":758},"NCT00167518","Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)",[87,88],"2005-04","2002-03",70,[18],[740],{"nctId":760,"briefTitle":761,"status":686,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":767},"NCT00148330","Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study",[87,88],"2008-07","2005-05",64,[18],[740],{"nctId":769,"briefTitle":770,"status":686,"phases":771,"primaryCompletion":772,"completion":772,"start":754,"enrollment":773,"conditions":774,"interventions":775},"NCT00148265","A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema",[87,88],"2009-05",54,[18],[740],{"trials":777,"activeCount":97},[],{"trials":779,"activeCount":97},[],{"intervention":781,"totalTrials":93,"cells":782},"Methoxyflurane",{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":801,"NA":803},{"trials":784,"activeCount":97},[],{"trials":786,"activeCount":97},[],{"trials":788,"activeCount":97},[],{"trials":790,"activeCount":97},[791],{"nctId":792,"briefTitle":793,"status":686,"phases":794,"primaryCompletion":795,"completion":796,"start":797,"enrollment":798,"conditions":799,"interventions":800},"NCT02604225","Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of TRUS B",[88],"2019-12-05","2019-12-30","2015-12",420,[25],[781],{"trials":802,"activeCount":97},[],{"trials":804,"activeCount":97},[],{"intervention":806,"totalTrials":93,"cells":807},"Bacillus of Calmette-Guerin",{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":814,"PHASE4":827,"NA":829},{"trials":809,"activeCount":97},[],{"trials":811,"activeCount":97},[],{"trials":813,"activeCount":97},[],{"trials":815,"activeCount":97},[816],{"nctId":817,"briefTitle":818,"status":594,"phases":819,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":823,"interventions":825},"NCT02948543","Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer",[88],"2024-12","2013-07",501,[824],"Bladder Cancer",[806,826],"Mitomycin",{"trials":828,"activeCount":97},[],{"trials":830,"activeCount":97},[],{"intervention":826,"totalTrials":93,"cells":832},{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":845,"NA":847},{"trials":834,"activeCount":97},[],{"trials":836,"activeCount":97},[],{"trials":838,"activeCount":97},[],{"trials":840,"activeCount":97},[841],{"nctId":817,"briefTitle":818,"status":594,"phases":842,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":843,"interventions":844},[88],[824],[806,826],{"trials":846,"activeCount":97},[],{"trials":848,"activeCount":97},[],{"intervention":850,"totalTrials":93,"cells":851},"Epoetin Alfa",{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":858,"PHASE4":872,"NA":874},{"trials":853,"activeCount":97},[],{"trials":855,"activeCount":97},[],{"trials":857,"activeCount":97},[],{"trials":859,"activeCount":97},[860],{"nctId":861,"briefTitle":862,"status":686,"phases":863,"primaryCompletion":864,"completion":865,"start":866,"enrollment":867,"conditions":868,"interventions":870},"NCT03079167","PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns",[88],"2023-11-30","2024-04-30","2016-05-14",313,[869],"Hypoxic-Ischemic Encephalopathy",[850,871],"Normal saline",{"trials":873,"activeCount":97},[],{"trials":875,"activeCount":97},[],{"intervention":871,"totalTrials":93,"cells":877},{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":884,"PHASE4":890,"NA":892},{"trials":879,"activeCount":97},[],{"trials":881,"activeCount":97},[],{"trials":883,"activeCount":97},[],{"trials":885,"activeCount":97},[886],{"nctId":861,"briefTitle":862,"status":686,"phases":887,"primaryCompletion":864,"completion":865,"start":866,"enrollment":867,"conditions":888,"interventions":889},[88],[869],[850,871],{"trials":891,"activeCount":97},[],{"trials":893,"activeCount":97},[],{"intervention":895,"totalTrials":93,"cells":896},"Avastin",{"EARLY_PHASE1":897,"PHASE1":899,"PHASE2":901,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":898,"activeCount":97},[],{"trials":900,"activeCount":97},[],{"trials":902,"activeCount":97},[903],{"nctId":904,"briefTitle":905,"status":686,"phases":906,"primaryCompletion":907,"completion":908,"start":909,"enrollment":910,"conditions":911,"interventions":914},"NCT01787669","Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema",[87],"2017-01","2017-10","2013-06",19,[912,18,913,20],"Diabetes","Diabetic Macular Edema",[895,915],"Ozurdex",{"trials":917,"activeCount":97},[],{"trials":919,"activeCount":97},[],{"trials":921,"activeCount":97},[],{"intervention":915,"totalTrials":93,"cells":923},{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":934,"PHASE4":936,"NA":938},{"trials":925,"activeCount":97},[],{"trials":927,"activeCount":97},[],{"trials":929,"activeCount":97},[930],{"nctId":904,"briefTitle":905,"status":686,"phases":931,"primaryCompletion":907,"completion":908,"start":909,"enrollment":910,"conditions":932,"interventions":933},[87],[912,18,913,20],[895,915],{"trials":935,"activeCount":97},[],{"trials":937,"activeCount":97},[],{"trials":939,"activeCount":97},[],{"intervention":941,"totalTrials":93,"cells":942},"bevacizumab",{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":944,"activeCount":97},[],{"trials":946,"activeCount":97},[],{"trials":948,"activeCount":97},[949],{"nctId":950,"briefTitle":951,"status":686,"phases":952,"primaryCompletion":953,"completion":953,"start":954,"enrollment":12,"conditions":955,"interventions":957},"NCT01298076","Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema",[87],"2014-09","2010-10",[20,956],"Macular Edema",[941,958],"dexamethasone",{"trials":960,"activeCount":97},[],{"trials":962,"activeCount":97},[],{"trials":964,"activeCount":97},[],{"intervention":958,"totalTrials":93,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":968,"activeCount":97},[],{"trials":970,"activeCount":97},[],{"trials":972,"activeCount":97},[973],{"nctId":950,"briefTitle":951,"status":686,"phases":974,"primaryCompletion":953,"completion":953,"start":954,"enrollment":12,"conditions":975,"interventions":976},[87],[20,956],[941,958],{"trials":978,"activeCount":97},[],{"trials":980,"activeCount":97},[],{"trials":982,"activeCount":97},[],{"intervention":984,"totalTrials":93,"cells":985},"Candesartan Cilexetil",{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":987,"activeCount":97},[],{"trials":989,"activeCount":97},[],{"trials":991,"activeCount":97},[992],{"nctId":993,"briefTitle":994,"status":995,"phases":996,"primaryCompletion":997,"completion":998,"start":999,"enrollment":1000,"conditions":1001,"interventions":1004},"NCT05122182","Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19","TERMINATED",[87],"2022-08-15","2023-01-28","2022-01-07",49,[1002,1003],"COVID-19","SARS-CoV2 Infection",[984,1005,1006,1007],"Repagermanium","Candesartan Placebo","Repagermanium Placebo",{"trials":1009,"activeCount":97},[],{"trials":1011,"activeCount":97},[],{"trials":1013,"activeCount":97},[],{"intervention":1005,"totalTrials":93,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1026,"PHASE4":1028,"NA":1030},{"trials":1017,"activeCount":97},[],{"trials":1019,"activeCount":97},[],{"trials":1021,"activeCount":97},[1022],{"nctId":993,"briefTitle":994,"status":995,"phases":1023,"primaryCompletion":997,"completion":998,"start":999,"enrollment":1000,"conditions":1024,"interventions":1025},[87],[1002,1003],[984,1005,1006,1007],{"trials":1027,"activeCount":97},[],{"trials":1029,"activeCount":97},[],{"trials":1031,"activeCount":97},[],{"intervention":1006,"totalTrials":93,"cells":1033},{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1035,"activeCount":97},[],{"trials":1037,"activeCount":97},[],{"trials":1039,"activeCount":97},[1040],{"nctId":993,"briefTitle":994,"status":995,"phases":1041,"primaryCompletion":997,"completion":998,"start":999,"enrollment":1000,"conditions":1042,"interventions":1043},[87],[1002,1003],[984,1005,1006,1007],{"trials":1045,"activeCount":97},[],{"trials":1047,"activeCount":97},[],{"trials":1049,"activeCount":97},[],{"intervention":1007,"totalTrials":93,"cells":1051},{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1062,"PHASE4":1064,"NA":1066},{"trials":1053,"activeCount":97},[],{"trials":1055,"activeCount":97},[],{"trials":1057,"activeCount":97},[1058],{"nctId":993,"briefTitle":994,"status":995,"phases":1059,"primaryCompletion":997,"completion":998,"start":999,"enrollment":1000,"conditions":1060,"interventions":1061},[87],[1002,1003],[984,1005,1006,1007],{"trials":1063,"activeCount":97},[],{"trials":1065,"activeCount":97},[],{"trials":1067,"activeCount":97},[],{"intervention":1069,"totalTrials":93,"cells":1070},"Tremelimumab",{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1072,"activeCount":97},[],{"trials":1074,"activeCount":97},[],{"trials":1076,"activeCount":97},[1077],{"nctId":1078,"briefTitle":1079,"status":594,"phases":1080,"primaryCompletion":1081,"completion":1082,"start":1083,"enrollment":1084,"conditions":1085,"interventions":1087},"NCT03994393","Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.",[87],"2023-06-30","2024-01-31","2018-10-23",100,[1086],"EGFR Mutant Advanced Non Small Cell Lung Cancer",[1069,1088],"Durvalumab",{"trials":1090,"activeCount":97},[],{"trials":1092,"activeCount":97},[],{"trials":1094,"activeCount":97},[],{"intervention":1088,"totalTrials":93,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1098,"activeCount":97},[],{"trials":1100,"activeCount":97},[],{"trials":1102,"activeCount":97},[1103],{"nctId":1078,"briefTitle":1079,"status":594,"phases":1104,"primaryCompletion":1081,"completion":1082,"start":1083,"enrollment":1084,"conditions":1105,"interventions":1106},[87],[1086],[1069,1088],{"trials":1108,"activeCount":97},[],{"trials":1110,"activeCount":97},[],{"trials":1112,"activeCount":97},[],{"intervention":1114,"totalTrials":93,"cells":1115},"Zoledronic Acid",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1131,"PHASE4":1133,"NA":1135},{"trials":1117,"activeCount":97},[],{"trials":1119,"activeCount":97},[],{"trials":1121,"activeCount":97},[1122],{"nctId":1123,"briefTitle":1124,"status":594,"phases":1125,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":598,"conditions":1128,"interventions":1130},"NCT00781261","Osteonecrosis of the Hip and Bisphosphonate Treatment",[87],"2013-12","2009-08",[1129],"Osteonecrosis",[1114],{"trials":1132,"activeCount":97},[],{"trials":1134,"activeCount":97},[],{"trials":1136,"activeCount":97},[],{"intervention":604,"totalTrials":93,"cells":1138},{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1149,"PHASE4":1151,"NA":1153},{"trials":1140,"activeCount":97},[],{"trials":1142,"activeCount":97},[],{"trials":1144,"activeCount":97},[1145],{"nctId":592,"briefTitle":593,"status":594,"phases":1146,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":1147,"interventions":1148},[87],[600,586,587,601,602],[604,571],{"trials":1150,"activeCount":97},[],{"trials":1152,"activeCount":97},[],{"trials":1154,"activeCount":97},[],{"intervention":1156,"totalTrials":93,"cells":1157},"Zostavax",{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1174,"PHASE4":1176,"NA":1178},{"trials":1159,"activeCount":97},[],{"trials":1161,"activeCount":97},[],{"trials":1163,"activeCount":97},[1164],{"nctId":1165,"briefTitle":1166,"status":686,"phases":1167,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1173},"NCT01573182","Herpes Zoster Vaccine for Bone Marrow Transplant Donors",[87],"2018-05-03","2012-04",8,[1172],"Herpes Zoster",[1156],{"trials":1175,"activeCount":97},[],{"trials":1177,"activeCount":97},[],{"trials":1179,"activeCount":97},[],{"intervention":1181,"totalTrials":93,"cells":1182},"Donor-derived WT1-CTL and P-CTL",{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1197,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1184,"activeCount":97},[],{"trials":1186,"activeCount":97},[1187],{"nctId":1188,"briefTitle":1189,"status":594,"phases":1190,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":1194,"interventions":1196},"NCT02895412","Infection and Tumour Antigen Cellular Therapy",[86],"2020-12","2016-08",20,[1195],"Leukemia, Myelocytic, Acute",[1181],{"trials":1198,"activeCount":97},[],{"trials":1200,"activeCount":97},[],{"trials":1202,"activeCount":97},[],{"trials":1204,"activeCount":97},[],{"intervention":1206,"totalTrials":93,"cells":1207},"Partially HLA-matched unrelated donor cells",{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1222,"PHASE3":1224,"PHASE4":1226,"NA":1228},{"trials":1209,"activeCount":97},[],{"trials":1211,"activeCount":97},[1212],{"nctId":1213,"briefTitle":1214,"status":594,"phases":1215,"primaryCompletion":1216,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1221},"NCT02189824","Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation",[86],"2016-12","2014-08",12,[1220],"Acute Myeloid Leukaemia",[1206],{"trials":1223,"activeCount":97},[],{"trials":1225,"activeCount":97},[],{"trials":1227,"activeCount":97},[],{"trials":1229,"activeCount":97},[],{"intervention":1231,"totalTrials":93,"cells":1232},"T-cell infusion, influenza vaccination",{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1246,"PHASE3":1248,"PHASE4":1250,"NA":1252},{"trials":1234,"activeCount":97},[],{"trials":1236,"activeCount":97},[1237],{"nctId":1238,"briefTitle":1239,"status":594,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1218,"conditions":1243,"interventions":1245},"NCT02843321","Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination",[86],"2017-12","2012-08",[1244],"Complication of Transplant",[1231],{"trials":1247,"activeCount":97},[],{"trials":1249,"activeCount":97},[],{"trials":1251,"activeCount":97},[],{"trials":1253,"activeCount":97},[],{"intervention":1255,"totalTrials":93,"cells":1256},"Virus specific CTLs",{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1273,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1258,"activeCount":97},[],{"trials":1260,"activeCount":97},[1261],{"nctId":1262,"briefTitle":1263,"status":594,"phases":1264,"primaryCompletion":1241,"completion":1265,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1272},"NCT02779439","Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation",[86],"2018-03","2013-01",25,[1269,1270,1271],"CMV Infection","EBV","Adenovirus",[1255],{"trials":1274,"activeCount":97},[],{"trials":1276,"activeCount":97},[],{"trials":1278,"activeCount":97},[],{"trials":1280,"activeCount":97},[],{"intervention":1282,"totalTrials":93,"cells":1283},"COVIGEN C19 0.8 mg ID or Placebo ID",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1285,"activeCount":97},[],{"trials":1287,"activeCount":97},[1288],{"nctId":1289,"briefTitle":1290,"status":686,"phases":1291,"primaryCompletion":1292,"completion":1293,"start":1294,"enrollment":1295,"conditions":1296,"interventions":1298},"NCT04742842","The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers",[86],"2022-07-30","2023-07-30","2021-06-21",68,[1297],"SARS-CoV2 COVID-19",[1282,1299,1300,1301],"COVIGEN C19 2.0 mg IM or Placebo IM","COVIGEN C19 4.0 mg IM or Placebo IM","COVIGEN C20 1.0mg vaccine ID",{"trials":1303,"activeCount":97},[],{"trials":1305,"activeCount":97},[],{"trials":1307,"activeCount":97},[],{"trials":1309,"activeCount":97},[],{"intervention":1299,"totalTrials":93,"cells":1311},{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1320,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1313,"activeCount":97},[],{"trials":1315,"activeCount":97},[1316],{"nctId":1289,"briefTitle":1290,"status":686,"phases":1317,"primaryCompletion":1292,"completion":1293,"start":1294,"enrollment":1295,"conditions":1318,"interventions":1319},[86],[1297],[1282,1299,1300,1301],{"trials":1321,"activeCount":97},[],{"trials":1323,"activeCount":97},[],{"trials":1325,"activeCount":97},[],{"trials":1327,"activeCount":97},[],{"intervention":1300,"totalTrials":93,"cells":1329},{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1344},{"trials":1331,"activeCount":97},[],{"trials":1333,"activeCount":97},[1334],{"nctId":1289,"briefTitle":1290,"status":686,"phases":1335,"primaryCompletion":1292,"completion":1293,"start":1294,"enrollment":1295,"conditions":1336,"interventions":1337},[86],[1297],[1282,1299,1300,1301],{"trials":1339,"activeCount":97},[],{"trials":1341,"activeCount":97},[],{"trials":1343,"activeCount":97},[],{"trials":1345,"activeCount":97},[],{"intervention":1301,"totalTrials":93,"cells":1347},{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1356,"PHASE3":1358,"PHASE4":1360,"NA":1362},{"trials":1349,"activeCount":97},[],{"trials":1351,"activeCount":97},[1352],{"nctId":1289,"briefTitle":1290,"status":686,"phases":1353,"primaryCompletion":1292,"completion":1293,"start":1294,"enrollment":1295,"conditions":1354,"interventions":1355},[86],[1297],[1282,1299,1300,1301],{"trials":1357,"activeCount":97},[],{"trials":1359,"activeCount":97},[],{"trials":1361,"activeCount":97},[],{"trials":1363,"activeCount":97},[]]